Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 5,399 matching trials from the live ClinicalTrials.gov search.
Filters: Tucson, Arizona Clear all
Completed Phase 2 Interventional

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT05811351
View directory record Official record
Conditions
Geographic Atrophy
Interventions
JNJ-81201887, Prednisone, Placebo, Triamcinolone, Sham Procedure
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 9, 2026, 5:57 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

NCT00648739
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions
Samalizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

NCT04003155
View directory record Official record
Conditions
Hot Flashes
Interventions
fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
72
States / cities
Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

NCT00702143
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
15
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Nov 9, 2026, 5:57 PM EST
Approved For Marketing No phase listed Expanded access

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

NCT01217697
View directory record Official record
Conditions
Prostate Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Genital Diseases, Male
Interventions
Abiraterone Acetate, Prednisone\Prednisolone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 154 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

NCT02555878
View directory record Official record
Conditions
Neoplasms
Interventions
Rivaroxaban, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
70
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 2 Interventional

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

NCT05159778
View directory record Official record
Conditions
Malignant Neoplasm of Breast
Interventions
Imprime PGG, Pembrolizumab
Biological
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

NCT01969708
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
aflibercept, bevacizumab
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Nov 9, 2026, 5:57 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

MIND-WELL Intervention

NCT07839325
View directory record Official record
Conditions
Lung Cancer (Diagnosis), Caregiver, Stress
Interventions
MIND-WELL Intervention (MINDfulness-based Intervention for Navigation of Dyadic WELLness and Education During Transitions)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 9, 2026, 5:57 PM EST
Completed Not applicable Interventional Results available

INtervention Study In overweiGHT Patients With COPD

NCT02634268
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Obesity, Weight Loss, Life Style, Overweight
Interventions
Lifestyle Intervention
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
40 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 3 Interventional Results available

Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.

NCT00356915
View directory record Official record
Conditions
Onychomycosis
Interventions
Itraconazole 100mg capsules, Itraconazole 200mg tablets, Placebo tablets
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
16 Years to 75 Years
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Birmingham, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Nov 9, 2026, 5:57 PM EST
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 3 Interventional

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

NCT01715818
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes Mellitus Type 2
Interventions
Placebo, aleglitazar
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
1,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
143
States / cities
Muscle Shoals, Alabama • Gilbert, Arizona • Phoenix, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 9, 2026, 5:57 PM EST
Completed Not applicable Interventional

Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis

NCT00002010
View directory record Official record
Conditions
Meningitis, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Tucson, Arizona • San Diego, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 9, 2026, 5:57 PM EST
Completed Not applicable Interventional

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

NCT03887520
View directory record Official record
Conditions
Cardiovascular Disease and Lipoprotein(a)
Interventions
Blood draw for Lp(a)
Diagnostic Test
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
180
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Nov 9, 2026, 5:57 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT01386385
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
232
States / cities
Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 2 Interventional Results available

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

NCT01693068
View directory record Official record
Conditions
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Interventions
Pimasertib, Dacarbazine
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Nov 9, 2026, 5:57 PM EST
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
347
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 9, 2026, 5:57 PM EST
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

NCT01678924
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
AGN-214868, AGN-214868 Placebo (Vehicle)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Mesa, Arizona • Tucson, Arizona • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

NCT03077438
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Years to 9 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
35
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

NCT00003955
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, filgrastim, pegfilgrastim, sargramostim, cyclophosphamide, irinotecan hydrochloride, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Nov 9, 2026, 5:57 PM EST
Recruiting No phase listed Observational

Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials

NCT05338697
View directory record Official record
Conditions
Stroke, Stroke, Acute, Stroke, Ischemic
Interventions
Transcranial Magnetic Stimulation (TMS)
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 9, 2026, 5:57 PM EST
Completed Phase 2 Interventional Results available

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

NCT00130520
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
bevacizumab, erlotinib
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Nov 9, 2026, 5:57 PM EST